Skip to main content
NACFC 2025 Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Session includes an in person invitee/speaker with CF
Session includes an in person invitee/speaker with CF
Livestreamed Session
Livestreamed Session
Recorded Session
Recorded Session
Session is Ticketed (Must Register for Session through Registration)
Session is Ticketed (Must Register for Session through Registration)
Food Available for Session Attendees
Food Available for Session Attendees
Session Feedback

APPTT

CLIN
Session Type: Thematic Poster Session

TPS05--Biomarkers of Disease Severity & Outcome Measures of Therapeutic Efficacy | Theater A Exhibit Hall

Friday, October 24, 2025
2:30 PM - 4:00 PM PDT
Location:Theater A Exhibit Hall

In the era of highly effective modulator therapy, the CF community continues to need biomarkers and outcome measures to accurately guide personalized treatments and improve long-term outcomes, as well as further develop new therapies for those who are ineligible or poorly responsive to currently available therapies. Attendees at this session will learn about novel research on known measures, such as sweat chloride and spirometry, as well as new predictive tools, monitoring strategies, and innovative approaches to measuring disease severity and response to interventions. This session consists of two main parts: poster viewing followed by a moderated discussion. It is designed to engage the authors and the audience in a discussion that ties together ideas from multiple posters in the session.

Learning Objectives:

  • Evaluate the role of emerging biomarkers and outcome measures, including sweat chloride, novel outcome measures, and imaging, to predict clinical outcomes and treatment response to CFTR modulators
  • Explore predictive and monitoring tools to improve CF care management
  • Investigate novel models and integrated outcome measures to stratify risk, guide therapeutic development, and personalize care for people with CF

Presentations:

  • 2:30 PM - 4:00 PM PDT
    TPS05.1- Parameter D: A novel biomarker to detect small airway disease through spirometry in CF

    Speaker: William T. Harris, Birmingham, AL – UAB

  • 2:30 PM - 4:00 PM PDT
    TPS05.3- Continuous glucose monitoring in young children with cystic fibrosis: a BEGIN sub-study

    Speaker: Katie Larson Ode, MD – University of Iowa

  • 2:30 PM - 4:00 PM PDT
    TPS05.4- Changes in sweat chloride concentrations following CFTR modulator treatment and association with antibiotic usage in adolescents and adults with CF

    Speaker: Sivagurunathan Sutharsan, MD – Department of Pulmonary Medicine, Division of Cystic Fibrosis, University Medicine Essen -Ruhrlandklinik, University of Duisburg-Essen, Essen, Germany.

  • 2:30 PM - 4:00 PM PDT
    TPS05.5- Maximizing benefits with early CFTR modulator treatment: Lower sweat chloride is associated with improved clinical outcomes in children aged 6 to 11 years

    Speaker: Emilio Arteaga-Solis, MD, PhD – Vertex Pharmaceutical

  • 2:30 PM - 4:00 PM PDT
    TPS05.6- Sweat sodium: chloride ratio differs in people with CF by CFTR modulator treatment status

    Speaker: Angela Metcalf, MD – University of Colorado School of Medicine

  • 2:30 PM - 4:00 PM PDT
    TPS05.7- Evaluation of the variability of exhaled breath profiles for the detection of Pseudomonas aeruginosa infections in CF: A longitudinal study

    Speaker: Josephine Ackah-Cudjoe, MSc – University of British Columbia

  • 2:30 PM - 4:00 PM PDT
    TPS05.8- Volatile biomarkers can differentiate methicillin-resistant and small-colony variant S. aureus subtypes

    Speaker: Daniela F. Gutierrez-Munoz – Arizona State University

  • 2:30 PM - 4:00 PM PDT
    TPS05.9- Is epigenetic age a marker of CF severity and drug response?

    Speaker: Lisa Strug, ScM, PhD – The Hospital for Sick Children